Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2012-12-23
AEs
2
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate BLOOD ALKALINE PHOSPHATASE INCREASED — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-12 (study day 141.0); relationship: NONE
moderate
assessed
Moderate HEADACHE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2011-11; relationship: NONE
Data queries
No data queries.